Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation: Current Evidence and Its Potential Role as First-Line Therapy

Pulsed-field ablation (PFA) is a novel, non-thermal energy modality that specifically targets the myocardium by using irreversible electroporation. This review summarizes the available data regarding the effectiveness, safety, and procedural time for PFA versus traditional thermal ablation for paroxysmal atrial fibrillation. While recent trials have shown that PFA results in outcomes comparable to those of radiofrequency ablation and cryoablation for rhythm control, they have also demonstrated a significant reduction in collateral damage to surrounding structures such as the esophagus and phrenic nerve. Faster procedure times, along with a more favorable safety profile for PFA, could offer advantages for patients and health care providers. Since preliminary evidence indicates PFA may be used safely and effectively as a first-line ablation therapy for AF, additional long-term data and larger-scale real-world analyses are needed to evaluate PFA's longevity and establish its role in routine clinical use. Overall, PFA offers a new direction for the development of catheter-based rhythm control therapies that are faster, safer, and more efficient than previously available options for atrial fibrillation.